Literature DB >> 18036698

Adenovirus vector induced innate immune responses: impact upon efficacy and toxicity in gene therapy and vaccine applications.

Zachary C Hartman1, Daniel M Appledorn, Andrea Amalfitano.   

Abstract

Extensively characterized, modified, and employed for a variety of purposes, adenovirus (Ad) vectors are generally regarded as having great potential by many applied virologists who wish to manipulate and use viral biology to achieve beneficial clinical outcomes. Despite widespread functional prominence and utility (i.e., Ad-based clinical trials have begun to progress to critical Phase III levels, it has recently become apparent that investigations regarding the innate immune response to Ads may reveal not only reasons behind previous failures, but also reveal novel insights that will allow for safer, more efficacious uses of this important gene transfer platform. Insights gained by the exploration of Ad induced innate immune responses will likely be most important to the fields of vaccine development, since Ad-based vaccines are regarded as one of the more promising vaccine platforms in development today. Adenovirus is currently known to interact with several different extracellular, intracellular, and membrane-bound innate immune sensing systems. Past and recent studies involving manipulation of the Ad infectious cycle as well as use of different mutants have shed light on some of the initiation mechanisms underlying Ad induced immune responses. More recent studies using microarray-based analyses, genetically modified cell lines and/or mouse mutants, and advanced generation Ad vectors have revealed important new insights into the scope and mechanism of this cellular defensive response. This review is an attempt to synthesize these studies, update Ad biologists to the current knowledge surrounding these increasingly important issues, as well as highlight areas where future research should be directed. It should also serve as a sobering reality to researchers exploring the use of any gene transfer vector, as to the complexities potentially involved when contemplating use of such vectors for human applications.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18036698      PMCID: PMC4039020          DOI: 10.1016/j.virusres.2007.10.005

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  110 in total

Review 1.  Immunity to adenovirus and adeno-associated viral vectors: implications for gene therapy.

Authors:  K Jooss; N Chirmule
Journal:  Gene Ther       Date:  2003-06       Impact factor: 5.250

2.  Selective depletion or blockade of Kupffer cells leads to enhanced and prolonged hepatic transgene expression using high-capacity adenoviral vectors.

Authors:  Gudrun Schiedner; Sabine Hertel; Marion Johnston; Volker Dries; Nico van Rooijen; Stefan Kochanek
Journal:  Mol Ther       Date:  2003-01       Impact factor: 11.454

3.  A replication competent adenovirus 5 host range mutant-simian immunodeficiency virus (SIV) recombinant priming/subunit protein boosting vaccine regimen induces broad, persistent SIV-specific cellular immunity to dominant and subdominant epitopes in Mamu-A*01 rhesus macaques.

Authors:  Nina Malkevitch; L Jean Patterson; Kristine Aldrich; Ersell Richardson; W Gregory Alvord; Marjorie Robert-Guroff
Journal:  J Immunol       Date:  2003-04-15       Impact factor: 5.422

4.  Human cytomegalovirus activates inflammatory cytokine responses via CD14 and Toll-like receptor 2.

Authors:  Teresa Compton; Evelyn A Kurt-Jones; Karl W Boehme; John Belko; Eicke Latz; Douglas T Golenbock; Robert W Finberg
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

5.  Efficient transduction of human monocyte-derived dendritic cells by chimpanzee-derived adenoviral vector.

Authors:  Andrei N Varnavski; Katia Schlienger; Jeffrey M Bergelson; Guang-Ping Gao; James M Wilson
Journal:  Hum Gene Ther       Date:  2003-04-10       Impact factor: 5.695

6.  Optimization of dendritic cell maturation and gene transfer by recombinant adenovirus.

Authors:  George Miller; Svenja Lahrs; Alaap B Shah; Ronald P DeMatteo
Journal:  Cancer Immunol Immunother       Date:  2003-03-12       Impact factor: 6.968

7.  The Toll-like receptor 5 stimulus bacterial flagellin induces maturation and chemokine production in human dendritic cells.

Authors:  Terry K Means; Fumitaka Hayashi; Kelly D Smith; Alan Aderem; Andrew D Luster
Journal:  J Immunol       Date:  2003-05-15       Impact factor: 5.422

Review 8.  Molecular basis of the inflammatory response to adenovirus vectors.

Authors:  Q Liu; D A Muruve
Journal:  Gene Ther       Date:  2003-06       Impact factor: 5.250

9.  The role of capsid-endothelial interactions in the innate immune response to adenovirus vectors.

Authors:  Qiang Liu; Anne K Zaiss; Pina Colarusso; Kamala Patel; Gregory Haljan; Thomas J Wickham; Daniel A Muruve
Journal:  Hum Gene Ther       Date:  2003-05-01       Impact factor: 5.695

10.  Adenovirus serotype 5 fiber shaft influences in vivo gene transfer in mice.

Authors:  Theodore A G Smith; Neeraja Idamakanti; Michele L Rollence; Jennifer Marshall-Neff; Jin Kim; Kathy Mulgrew; Glen R Nemerow; Michael Kaleko; Susan C Stevenson
Journal:  Hum Gene Ther       Date:  2003-05-20       Impact factor: 5.695

View more
  88 in total

1.  Optimized adenovirus-antibody complexes stimulate strong cellular and humoral immune responses against an encoded antigen in naive mice and those with preexisting immunity.

Authors:  Jin Huk Choi; Joe Dekker; Stephen C Schafer; Jobby John; Craig E Whitfill; Christopher S Petty; Eid E Haddad; Maria A Croyle
Journal:  Clin Vaccine Immunol       Date:  2011-11-16

2.  Adenovirus capsid-display of the retro-oriented human complement inhibitor DAF reduces Ad vector-triggered immune responses in vitro and in vivo.

Authors:  Sergey S Seregin; Yasser A Aldhamen; Daniel M Appledorn; Zachary C Hartman; Nathaniel J Schuldt; Jeannine Scott; Sarah Godbehere; Haixiang Jiang; Michael M Frank; Andrea Amalfitano
Journal:  Blood       Date:  2010-05-28       Impact factor: 22.113

3.  Multiple innate immune pathways contribute to the immunogenicity of recombinant adenovirus vaccine vectors.

Authors:  Elizabeth G Rhee; Joseph N Blattman; Sudhir P Kasturi; R Phelps Kelley; David R Kaufman; Diana M Lynch; Annalena La Porte; Nathaniel L Simmons; Sarah L Clark; Bali Pulendran; Philip D Greenberg; Dan H Barouch
Journal:  J Virol       Date:  2010-10-20       Impact factor: 5.103

Review 4.  Engineering Cell Fate for Tissue Regeneration by In Vivo Transdifferentiation.

Authors:  I de Lázaro; K Kostarelos
Journal:  Stem Cell Rev Rep       Date:  2016-02       Impact factor: 5.739

Review 5.  Progress on adenovirus-vectored universal influenza vaccines.

Authors:  Kui Xiang; Guan Ying; Zhou Yan; Yan Shanshan; Zhang Lei; Li Hongjun; Sun Maosheng
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 6.  Electroporation for the delivery of DNA-based vaccines and immunotherapeutics: current clinical developments.

Authors:  Angela M Bodles-Brakhop; Richard Heller; Ruxandra Draghia-Akli
Journal:  Mol Ther       Date:  2009-02-17       Impact factor: 11.454

Review 7.  Biological gene delivery vehicles: beyond viral vectors.

Authors:  Yiqi Seow; Matthew J Wood
Journal:  Mol Ther       Date:  2009-03-10       Impact factor: 11.454

8.  Transient pretreatment with glucocorticoid ablates innate toxicity of systemically delivered adenoviral vectors without reducing efficacy.

Authors:  Sergey S Seregin; Daniel M Appledorn; Aaron J McBride; Nathaniel J Schuldt; Yasser A Aldhamen; Tyler Voss; Junping Wei; Matthew Bujold; William Nance; Sarah Godbehere; Andrea Amalfitano
Journal:  Mol Ther       Date:  2009-01-27       Impact factor: 11.454

Review 9.  Antioxidant enzyme gene transfer for ischemic diseases.

Authors:  Jian Wu; James G Hecker; Nipavan Chiamvimonvat
Journal:  Adv Drug Deliv Rev       Date:  2009-02-20       Impact factor: 15.470

10.  Induction of shock after intravenous injection of adenovirus vectors: a critical role for platelet-activating factor.

Authors:  Zhili Xu; Jeffrey S Smith; Jie Tian; Andrew P Byrnes
Journal:  Mol Ther       Date:  2009-12-01       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.